POLYMERIC MICELLES CO-LOADED WITH PACLITAXEL AND HISTAMINE AS A NEW STRATEGY TO IMPROVE CONVENTIONAL CHEMOTHERAPY FOR BREAST CANCER

NICOUD, M.B.; OSPITAL, IGNACIO A.; TÁQUEZ DELGADO, MÓNICA A.; RIEDEL, JENNIFER; FUENTES, PEDRO; BERNABEU, EZEQUIEL; MORETTON, MARCELA A.; RUBINSTEIN, MARA R.; SALGUEIRO, MARÍA J.; LAURETTA, PAOLO; CHIAPPETTA, DIEGO A.; MEDINA, VANINA A

Mar del Plata

Congreso; LXVII Reunión Anual de la SAIC, Sociedad Argentina de Investigación Clínica; 2022

Sociedad Argentina de Investigación Clínica

Breast cancer is now the most commonly diagnosed cancer and theleading cause of cancer death in women worldwide. Triple negativebreast cancer (TNBC) is the most aggressive subtype, associatedwith the worst prognosis. Non-specific chemotherapeutic drug paclitaxel(PTX) is used as the standard regimen, but its poor solubilityand several associated adverse effects conditioned its clinical use.The aim of this work was to improve the chemotherapeutic responseof PTX by developing new nanomicellars polymeric formulations.Micellar systems were developed with the biocompatible polymerSoluplus® (S), surface decorated with glucose residues (SG) andco-loaded with histamine (HA, 5 mg/mL) and PTX (4 mg/mL). Theirphysicochemical characterization includes the determination of micellarsize and its distribution, zeta potential and physical stability.We evaluated antitumor activity in human MDA-MB-231 and murine4T1 TNBC cells. Cytotoxicity and apoptotic assays showedthat HA-PTX co-loaded micelles exhibited better antitumor activitycompared to free PTX and Genexol® (commercial micellar-basedPTX-nanoformulation) and single treatments loaded micelles in bothcell lines (P